| Dr Arthur Molina Iii, MD | |
|
1211 24th St, Anacortes, WA 98221-2562 | |
| (360) 293-3101 | |
| Not Available |
| Full Name | Dr Arthur Molina Iii |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 30 Years |
| Location | 1211 24th St, Anacortes, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699718007 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RX0202X | Internal Medicine - Medical Oncology | MD00034534 (Washington) | Primary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD00034534 (Washington) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Skagit Valley Hospital | Mount vernon, WA | Hospital |
| Island Hospital | Anacortes, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cancer Care Northwest Centers P S | 4688561939 | 41 |
News Archive
The President's Emergency Plan for AIDS Relief is "dead on track" to meet its goal of providing antiretroviral drugs to two million people when it's five-year authorization expires in 2008, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, said Thursday in an interview during a visit to San Francisco, the San Francisco Chronicle reports.
Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
A new study suggests that the handwriting problems that affect children with autism are likely to continue into their teenage years.
Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
The President's Emergency Plan for AIDS Relief is "dead on track" to meet its goal of providing antiretroviral drugs to two million people when it's five-year authorization expires in 2008, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, said Thursday in an interview during a visit to San Francisco, the San Francisco Chronicle reports.
Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
A new study suggests that the handwriting problems that affect children with autism are likely to continue into their teenage years.
Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.
› Verified 1 days ago
| Entity Name | Public Hospital District No 2 Skagit County Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740203967 PECOS PAC ID: 1153225198 Enrollment ID: O20031121000440 |
News Archive
The President's Emergency Plan for AIDS Relief is "dead on track" to meet its goal of providing antiretroviral drugs to two million people when it's five-year authorization expires in 2008, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, said Thursday in an interview during a visit to San Francisco, the San Francisco Chronicle reports.
Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
A new study suggests that the handwriting problems that affect children with autism are likely to continue into their teenage years.
Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.
› Verified 1 days ago
| Entity Name | Cancer Care Northwest Centers P S |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922072081 PECOS PAC ID: 4688561939 Enrollment ID: O20040302000160 |
News Archive
The President's Emergency Plan for AIDS Relief is "dead on track" to meet its goal of providing antiretroviral drugs to two million people when it's five-year authorization expires in 2008, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, said Thursday in an interview during a visit to San Francisco, the San Francisco Chronicle reports.
Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
A new study suggests that the handwriting problems that affect children with autism are likely to continue into their teenage years.
Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.
› Verified 1 days ago
| Entity Name | Public Hospital Dist No 1 Skagit |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1629012463 PECOS PAC ID: 6800793522 Enrollment ID: O20080506000040 |
News Archive
The President's Emergency Plan for AIDS Relief is "dead on track" to meet its goal of providing antiretroviral drugs to two million people when it's five-year authorization expires in 2008, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, said Thursday in an interview during a visit to San Francisco, the San Francisco Chronicle reports.
Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
A new study suggests that the handwriting problems that affect children with autism are likely to continue into their teenage years.
Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Arthur Molina Iii, MD 1211 24th St, Anacortes, WA 98221-2562 Ph: (360) 293-3101 | Dr Arthur Molina Iii, MD 1211 24th St, Anacortes, WA 98221-2562 Ph: (360) 293-3101 |
News Archive
The President's Emergency Plan for AIDS Relief is "dead on track" to meet its goal of providing antiretroviral drugs to two million people when it's five-year authorization expires in 2008, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, said Thursday in an interview during a visit to San Francisco, the San Francisco Chronicle reports.
Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
A new study suggests that the handwriting problems that affect children with autism are likely to continue into their teenage years.
Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.
› Verified 1 days ago
Charles Vladimir Kotal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 912 32nd St., Ste A, Anacortes, WA 98221 Phone: 360-416-5750 Fax: 360-416-5758 | |
Mr. Richard Roy Holman, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1211 24th St, Anacortes, WA 98221 Phone: 360-299-1300 | |
Greg G. Monaghan, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 2908 17th St., Anacortes, WA 98221 Phone: 913-638-2675 | |
Helen Yingqing Young, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 912 32nd Street, Suite A, Anacortes, WA 98221 Phone: 360-293-4343 Fax: 360-588-1587 | |
Allen Horesh, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 912 32nd St, Suite A, Anacortes, WA 98221 Phone: 360-293-4343 | |
Georgia Marie Leake, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1211 24th St, Anacortes, WA 98221 Phone: 360-299-1300 |